Neurocrine Biosciences Inc (NBIX) Stock Price
NBIXStock
$135.71−1.32%52W
Market Cap$13.79B
P/E28.82x
PEG Ratio0.28
Div yield—
Beta0.34
NBIX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-6.16%
Price vs S&P 500 (4W)-4.41%
PEG Ratio0.28
VGM Score61.41
P/E Ratio (Annual)28.82x
NBIX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.96 | $2.85 | +45.44%(+$0.89) | |
| Q1 2026 | $1.70 | $1.94 | +14.36%(+$0.24) | |
| Q4 2025 | $2.30 | $1.88 | -18.13%(-$0.42) | |
| Q3 2025 | $2.07 | $2.17 | +4.89%(+$0.10) | |
| Q2 2025 | $1.50 | $1.65 | +9.64%(+$0.15) |
NBIX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.25
4.24
4.25
4.25
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| TECHBio-Techne Corp. | D | C | B | 9.4x | -0.4% | 66.2% | 6.0% | $72.57 |
About Neurocrine Biosciences Inc
Neurocrine Biosciences develops and commercializes pharmaceutical treatments for neurological, psychiatric, endocrine, and immunological disorders. Key marketed products address tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids, while a pipeline of candidates spans multiple therapeutic modalities including small molecules, peptides, proteins, antibodies, and gene therapies. The company generates revenue from pharmaceutical product sales.